Ionis Pharmaceuticals (NASDAQ: IONS) director Peter Reikes files baseline Form 3

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC filed an initial Form 3 for Peter N. Reikes, who is identified as a director of the company and not a ten percent owner or officer. The filing reports no transactions or holdings data, serving as a baseline statement of beneficial ownership.

Key Terms

Form 3, beneficial ownership, director, ten percent owner

4 terms

Form 3 regulatory

"filed an initial Form 3 for Peter N. Reikes"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"serving as a baseline statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

director financial

"identified as a director of the company"

ten percent owner financial

"not a ten percent owner or officer"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reikes Peter N

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2026

3. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	By: Patrick R. O'Neil, attorney-in-fact For: Peter N. Reikes	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Ionis Pharmaceuticals (IONS) Form 3 for Peter N. Reikes show?

The Form 3 identifies Peter N. Reikes as a director of Ionis Pharmaceuticals and not a ten percent owner or officer. It reports no transactions or holdings, functioning as an initial beneficial ownership baseline for future Form 4 or Form 5 updates.

Did Peter N. Reikes buy or sell any Ionis Pharmaceuticals (IONS) shares in this Form 3?

No, this Form 3 does not show any purchases, sales, or other share transactions by Peter N. Reikes. All transaction-related counts are zero, indicating this filing only establishes his status as a reporting director with no activity disclosed here.

Is Peter N. Reikes a ten percent owner of Ionis Pharmaceuticals (IONS) according to this filing?

No, the filing explicitly indicates that Peter N. Reikes is not a ten percent owner of Ionis Pharmaceuticals. He is reported solely as a director, with officer status and ten percent owner status both shown as not applicable in this document.

Does the Ionis Pharmaceuticals (IONS) Form 3 for Peter N. Reikes include derivative positions?

No, the derivativeSummary section is empty and derivativeTransactionCount is zero in the transaction summary. This means the Form 3 does not disclose any options, warrants, or other derivative securities for Peter N. Reikes in this initial ownership statement.

How much trading activity is shown for Peter N. Reikes in Ionis Pharmaceuticals (IONS) shares?

The Form 3 shows no trading activity for Peter N. Reikes. Buy, sell, acquire, dispose, exercise, gift, tax withholding, and restructuring counts are all zero, and netBuySellDirection is listed as neutral, indicating no share movement is reported here.